Immune Response To Antigens

Overview

About this study

The purpose of this study is to sequence patient germline and tumor samples, and nominate top neoantigen candidates using an in-house developed bioinformatics pipeline, and to validate the neoantigen candidates by laboratory assays using patient peripheral blood immune cells or serum.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Age > 18 years
For cancer patients:
- 10 samples from each of the following cancers: breast, bladder, cervical, colorectal, head and neck, liver, lung, kidney, skin, stomach, as well as Hodgkin lymphoma.
- Stages II, III, or IV disease.
Provide written informed consent.

Willingness to provide blood samples for neoantigen validation and T-cell activity assays

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Jacksonville, Fla. Mayo Clinic principal investigator Yan Asmann, Ph.D.	Open for enrollment	Contact information: Yan Asmann 9049536717 asmann.yan@mayo.edu

Mayo Clinic Location

Status

Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Yan Asmann, Ph.D.

Open for enrollment

Contact information:

Yan Asmann

9049536717

asmann.yan@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials